PeptiDream, Ipsen Widen Research Pact To Cover Endocrinoligic Diseases
This article was originally published in PharmAsia News
PeptiDream and Ipsen have agreed to expand their six-month-old research collaboration to cover discovery-to-market therapeutic peptides for serious medical conditions.
You may also be interested in...
A draft guidance document by the US FDA that tackles medical device cybersecurity will likely be issued in the next several months, says Linda Ricci, a health scientist for the agency’s Office of Device Evaluation. Check out her comments on cybersecurity here.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.